PROSTATАNING KLINIK AHAMIYATLI SARATONINI ANIQLASHDA MULTIPARAMETRIK MRT VA PSA DENSITYNING DIAGNOSTIK AHAMIYATI
Keywords:
Kalit so‘zlar: prostata saratoni, klinik ahamiyatli prostata saratoni, multiparametrik MRT, PSA density, PSA, PI-RADS, prostata biopsiyasi, diagnostika.Abstract
Annotatsiya. Prostata saratonini, ayniqsa klinik ahamiyatli shakllarini erta
aniqlash zamonaviy urologiyaning dolzarb masalalaridan biridir. Multiparametrik
magnit-rezonans tomografiya (mpMRT) prostata bezidagi patologik o‘choqlarni
aniqlash va ularning klinik ahamiyatini baholashda muhim diagnostik usul hisoblanadi.
PSA density (PSAD) esa prostata-spetsifik antigen darajasini prostata hajmiga nisbatan
baholash imkonini berib, prostata saratoni xavfini aniqroq stratifikatsiya qilishga
yordam beradi. mpMRT natijalari va PSAD ko‘rsatkichlarini kompleks baholash klinik
ahamiyatli prostata saratonini aniqlash samaradorligini oshirishi hamda biopsiya
o‘tkazish taktikasini optimallashtirishi mumkin. Ushbu yondashuv bemorlarni xavf
guruhlariga ajratish va diagnostik qarorlarni individuallashtirishda muhim ahamiyatga
ega.
References
Foydalanilgan adabiyotlar
1. Oerther B., Nedelcu A., Engel H. et al. Update on PI-RADS Version 2.1
Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and
Meta-Analysis // Radiology. – 2024. – Vol. 312, No. 2. – Article e233337. – DOI:
10.1148/radiol.233337.
2. Wang S., Kozarek J., Russell R. et al. Diagnostic Performance of Prostate-
specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-
analysis // European Urology Oncology. – 2024. – Vol. 7, No. 2. – P. 189–203.
– DOI: 10.1016/j.euo.2023.08.002.
3. Woo S., Suh C.H., Kim S.Y. et al. Diagnostic Performance of Prostate Imaging
Reporting and Data System Version 2.1 for Clinically Significant Prostate
Cancer: A Systematic Review and Meta-analysis // Journal of Magnetic
Resonance Imaging. – 2021. – Vol. 54, No. 1. – P. 118–128. – DOI:
10.1002/jmri.27546.
4. European Association of Urology. EAU Guidelines on Prostate Cancer.
Diagnostic Evaluation. – 2026. – Arnhem: EAU Guidelines Office.
5. Deng X.J., Zhang H.C., Zhang J. et al. Diagnostic performance of PI-RADS v2.1
for clinically significant prostate cancer in the peripheral, transitional and
multiple zones // Zhonghua Nan Ke Xue. – 2024. – Vol. 30, No. 11. – P. 982–
986.
